LiVeritas Biosciences provides Mass Spectrometry as a Service (MSaaS) to accelerate the testing of drug quality, safety, and efficacy, achieving results in under three weeks. The platform addresses inefficiencies in traditional testing methods by offering tailored analytical workflows and rapid data interpretation for biopharma companies seeking FDA approval.
Funding
$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biopharmaceutical companies face challenges in efficiently and accurately testing drug quality, safety, and efficacy due to outdated testing processes, data compatibility issues, and a lack of expertise in extracting actionable insights from complex data. Traditional testing methods can be time-consuming and may not provide the rapid data interpretation needed to accelerate drug development and FDA approval.
Solution
LiVeritas Biosciences offers Mass Spectrometry as a Service (MSaaS), a streamlined LC-MS workflow designed to accelerate drug development. MSaaS provides biopharma companies with tailored analytical workflows and rapid data interpretation, achieving results in under three weeks. The service begins with client-expert consultations to define project objectives, followed by sample submission and analytical method screening. Data is acquired using ultra-high resolution LC-MS instrumentation, processed, and interpreted using proprietary tools and biopharma expertise. Clients receive a comprehensive report with in-depth characterization, identification, and quantitation of drug candidates.
Target Audience
LiVeritas Biosciences serves biopharmaceutical companies seeking to accelerate drug research and development, including those working on antibody-derived drugs, ADCs, gene and cell therapies, and novel proteins.
Features
- Streamlined LC-MS workflow from sample to report in under three weeks
- Client-expert consultations to define phase-appropriate project objectives
- Analytical method screening and development for optimal sample analysis
- Data processing and interpretation using proprietary tools and biopharma expertise
- Comprehensive results reporting with LC-MS chromatograms, mass spectra, quantitation, and profiling
- cGMP capabilities including appearance, pH, osmolality, protein concentration, CE-SDS, iCIEF, SEC-UV, RPLC-UV, peptide map LC-UV-MS, and antigen binding by ELISA
- Analytical strategy aligned with CMC strategy
- Capabilities span diverse modalities including bispecific antibodies, ADCs, gene & cell therapy, and oligonucleotides